W. Thomas Purcell

Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients

Jacob J. Chabon, Andrew D. Simmons, Alexander F. Lovejoy et al. · Nature Communications · 2016 · 659 citations · Full text

Medicine, Oncology, Pharmacology +17

The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non–Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib

Tejas Patil, Derek Smith, Paul A. Bunn et al. · Journal of Thoracic Oncology · 2018 · 199 citations · Full text

Medicine, Oncology, Metastasis +13

Therapy of Advanced Non–Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan

Rebecca S. Heist, Michael J. Guarino, Gregory A. Masters et al. · Journal of Clinical Oncology · 2017 · 190 citations

Medicine, Oncology, Pharmacology +15

Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I–inhibiting Antibody–Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan

Jhanelle E. Gray, Rebecca S. Heist, Alexander Starodub et al. · Clinical Cancer Research · 2017 · 159 citations · Full text

Medicine, Oncology, Pharmacology +17

Clinical Utility of Cell-Free DNA for the Detection of <i>ALK</i> Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non–Small Cell Lung Cancer

Caroline E. McCoach, Collin M. Blakely, Kimberly C. Banks et al. · Clinical Cancer Research · 2018 · 153 citations

Medicine, Molecular Genetics, Oncology +17